Stockreport

Nurix Announces FDA Clearance of IND Application for GS-6791/NX-0479 - a Novel IRAK4 Degrader for Inflammatory Conditions [Yahoo! Finance]

Nurix Therapeutics, Inc. - Common stock  (NRIX) 
PDF GS-6791/NX-0479 has potential clinical applications across multiple blockbuster markets in inflammation, in both rheumatology and dermatology, including rheumatoid arth [Read more]